Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Chemistry
Emerging Technology
Immunoassays
Molecular Diagnostics
Pathology & AI
Gene expression
Polygenic risk scores from multi-ancestry GWASs more accurate in diverse groups: Study
Polygenic risk scores (PRS) derived from multi-ancestry genome-wide association studies (GWASs) outperform PRSs based on single-ancestry GWASs in underrepresented populations, new research shows.
September 21, 2023
Castle Biosciences Pittsburgh lab receives N.Y. state permit
Castle Biosciences has received a clinical laboratory permit from the New York State Department of Health for its Pittsburgh laboratory.
September 13, 2023
Gene expression test may improve diagnosis of febrile childhood diseases
A simple blood test based on patterns of gene expression could radically improve and speed up the diagnosis of febrile childhood diseases, say researchers.
August 30, 2023
Gene-specific approach recommended for variant pathogenicity prediction
A research team investigated the efficacy of gene-specific supervised machine learning in predicting the pathogenicity of rare BRCA1/2 missense variants compared to the disease-specific approach.
August 22, 2023
CareDx lands Medicare coverage for heart transplant surveillance testing
The testing service, branded HeartCare, features AlloMap Heart and AlloSure Heart, both of which have individual Medicare coverage.
August 9, 2023
CareDx reports 13% second-quarter revenue decrease from previous year
The company expects full-year 2023 revenues to be in the range of $240 million to $260 million.
August 9, 2023
Viome launches at-home oral disease test
Viome uses the test results to provide consumers with customized food and supplement recommendations that support an individual’s oral and overall health, according to the company.
August 7, 2023
Quest Diagnostics launches consumer-initiated genetic test kit
The test uses next-generation sequencing (NGS) technology to analyze thousands of DNA variants in the genes associated with the conditions within the test’s scope, searching more regions in the individual’s genome than microarray testing.
July 12, 2023
Castle Biosciences reports study validation for melanoma gene expression test
The study findings support results from a recently published study which showed that patients who received routine imaging guided by high-risk 31-GEP test scores had earlier diagnoses of recurrence, which in turn led to better outcomes for patients.
July 6, 2023
Biocartis, HiloProbe collaborating to commercialize, distribute colorectal cancer gene-expression test
The test, ColoNode, is CE-marked and will be distributed first as a manual kit by Biocartis to expert laboratories in selected European countries.
May 9, 2023
Oncocyte to lay off 20% of workforce in cost restructuring
The CEO said the layoff is part of a plan to bring its cost structure in line with its kitted product strategy and to optimize operational efficiency.
April 13, 2023
Oncocyte prices $13.86M public offering to support test development, commercialization
Oncocyte intends to use the net proceeds from the offering primarily to promote the development and commercialization of VitaGraft, DetermaIO, and DetermaCNI precision diagnostic tests.
April 3, 2023
Page 1 of 3
Next Page
